Dr Stephen Oh discusses risk assessment in patients with essential thrombocythemia.
Videos
Stephen Oh, MD, PhD, reviews the case of a 46-year-old female with essential thrombocythemia.
Experts in hematology/oncology review data from the UNITY-NHL trial and share insights on the sequencing of therapies in R/R FL and MZL.
Ian W. Flinn, MD, PhD, and Jason M. Melear, MD, review the tolerability and efficacy of umbralisib in the management of R/R FL and MZL.
Expert hematologist/oncologists comment on the safety profile of PI3K inhibitors when treating R/R FL and MZL and share their approach to managing associated adverse events.
Ian W. Flinn, MD, PhD, and Jason M. Melear, MD, review clinical trial data for idelalisib, copanlisib, and duvelisib and discuss their personal experience using these agents for the management of R/R FL and MZL.
Rajneesh Nath, MD, discusses outcomes for older patients with acute myeloid leukemia.
The panel discusses treatment options and considerations for a 53-year-old woman with PD-L1+ triple-negative breast cancer.
Carey Anders, MD, and Andrew Seidman, MD, share their recommendations for HER2+ breast cancer recurrence within 12 months of HP.
The panel of experts review the study design and key efficacy data of the KEYNOTE-355 trial.
The panel of experts in breast cancer discuss treatment options when the cancer has metastasized.
Experts in breast cancer discuss efficacy data from the IMpassion130 clinical trial.
Elizabeth Mittendorf, MD, PhD, reviews the case of a 53-year-old woman with PD-L1+ TNBC breast cancer and the panel discusses relevant clinical trial data.
Ingrid Mayer, MD, MSCI, presents the case of a patient with high-risk HR+/HER2+ breast cancer who develops recurrence after a long disease-free interval.
Thomas Bachelot, MD, PhD, discusses therapies available for patients with HER2-positive breast cancer and brain metastases.
Marie E. Cabanillas, MD, an oncologic endocrinologist at the University of Texas MD Anderson Cancer Center, discusses current unmet needs in advanced or metastatic TRK fusion-Positive thyroid cancer.
Mitul Gandhi, MD, discusses the current landscape for patients with diffuse large B-cell lymphoma and what may be coming in the future.
Nadia Harbeck, MD, PhD, discusses how the monarchE trial, which evaluated the efficacy of endocrine therapy with or without abemaciclib, will change breast cancer treatment.
Looking ahead, Loretta Nastoupil, MD, reviews the future direction and unmet needs in the management of relapsed/refractory follicular lymphoma (R/R FL).
Dr Loretta Nastoupil describes best practices for managing the side effects of tazemetostat in patients with R/R FL.
Loretta Nastoupil, MD, discusses the use of tazemetostat in patients with and without an EZH2m.
Loretta Nastoupil, MD, describes the challenges of selecting treatment beyond the second-line.
Loretta Nastoupil, MD, describes the challenges of selecting treatment beyond the second-line.
A key opinion leader in the treatment of FL provides insight on the decision of whether to add maintenance therapy to the treatment regimen.
Loretta Nastoupil, MD, discusses first-line therapy options for patients with newly diagnosed follicular lymphoma (ND FL).
Loretta Nastoupil, MD, describes the role of molecular testing used in risk stratification of patient with FL
Loretta Nastoupil, MD, reviews the case of a 75-year-old woman with relapsed/refractory follicular lymphoma (R/R FL).
Expert hematologist/oncologists discuss the use of early PI3K inhibitors in the management of R/R follicular lymphoma (FL) and MZL (marginal zone lymphoma).
Ian W. Flinn, MD, PhD, leads the discussion on the various PI3K isoforms and their role in lymphoma.
Ruben Mesa, MD, and panel discuss considerations for optimizing therapy in high risk myelofibrosis.